Deanne Randolph
Vice President of Commercial Development
Replay available
PDS Biotechnology Corporation (NASDAQ: PDSB) Q2 2021 earnings conference call, held 2021-08-12. Replay captured from the company's public earnings webcast.

Vice President of Commercial Development
Chief Executive Officer
Chief Medical Officer
Chief Financial Officer
Analyst, Cantor Fitzgerald & Co.
Analyst, Oppenheimer & Co.
Analyst, H.C. Wainwright & Co.
Analyst, Noble Capital Markets
Analyst, Alliance Global Partners
Greetings, and welcome to PDS Biotechnology's second quarter 2021 financial results. At this time, all participants are in a listen-only mode. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Deanne Randolph, Vice President of Commercial Development. Please go ahead. Good morning, and welcome to PDS Biotechnology's second quarter 2021 earnings conference call and audio webcast. With me today are Dr. Frank Badu-Otto, Chief Executive Officer, Dr. Lauren B. Wood, Chief Medical Officer, and Dr. Seth Van Voorhees, Chief Financial Officer. Earlier this morning, PDS Biotech issued a press release announcing financial results for the quarter ended June 30, 2021. We encourage everyone to read the press release as well as PDS Biotech's quarterly report on Form 10-Q, which was filed with the SEC earlier this morning. The company's press release is available on PDS Biotech's website at pdsbiotech.com, and the quarterly report will be posted later today. In addition, the conference calls and webcasts include the company's website and will be archived there for future reference. Before we begin, I would like to caution listeners that comments made by management during this conference call will include forward-looking statements within the meaning of federal securities laws, including the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve material risks and uncertainties, and the company's actual results may differ materially. For discussion of these risk factors, including among others, the risks related to COVID-19, The impact such pande...